ALMIRALL HERMAL GmbH

ACTIVE

Scholtzstr. 3, Reinbek, Schleswig-Holstein, Germanywww.almirall.deSubsidiary1,001–5,000 employeesEstablished: 1943-01-01

Part of ALMIRALL SA

Clinical Trials

25 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1943

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

17.9%

Trial Status Distribution

Active, not recruiting

89.3%

Completed

10.7%

Clinical Trials

Trials sponsored by this organization (28)

Tirbanibulin 1% Ointment in field therapy for the treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis on the face or scalp in adults

Completed

observational

Jan 2022549 participants

SATIVEX® AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS

Phase 1

Active, not recruiting

Jan 2016228 participants

SATIVEX® AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS

Phase 1

Active, not recruiting

Dec 2015228 participants

Vehicle controlled study to evaluate the efficacy and safety of Actikerall® solution in the field-directed treatment of actinic keratoses grade I to II

Phase 1

Active, not recruiting

Jul 2014162 participants

Vehicle controlled study to evaluate the efficacy and safety of Actikerall® solution in the field-directed treatment of actinic keratoses grade I to II

Active, not recruiting

Jul 2014162 participants

A phase IIa, 28-day treatment, multi-center, randomized, comparator-controlled, observer-blind trial with intra-individual left/right comparison to investigate the anti-psoriatic efficacy and the safety of an LAS41004 formulation in comparison to an active reference in patients with mild to moderate plaque psoriasis

Phase 1

Active, not recruiting

Jan 201440 participants

on-interventional study investigating Actikerall® II in patients with actinic keratosis (clinical grade I or II according to Olsen) on hands and/or underarms

Completed

observational

Jan 2014649 participants

A phase II trial to evaluate the anti-psoriatic efficacy and tolerability of tazarotene in a gel formulation in patients with mild to moderate nail psoriasis - parallel group compariso

Active, not recruiting

Nov 2013

Page 1 of 4

Approvals

Approvals by Agency

SFDA

Saudi Food and Drug Authority

Approvals

NPRA

National Pharmaceutical Regulatory Agency

Approvals

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

Approvals

Recent Approvals

VERRUMAL SOLUTION

NPRA

2025-11-28

Finjuve for Men Cutaneous Spray Solution 2.275 mg/mL

MOMETASONA ALMIRALL 1 MG/G EMULSION CUTANEA

CIMA_AEMPS

2014-01-13

ACTIKERALL 5 MG/G + 100 MG/G SOLUCION CUTANEA

CIMA_AEMPS

2013-07-01

News

No news articles found

Back to Organizations